[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07660640":3,"trial-entities:NCT07660640":95,"trial-summary:NCT07660640":99},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":23,"primary_purpose":24,"phases":25,"enrollment_info":26,"interventions":29,"primary_outcomes":41,"secondary_outcomes":46,"sex":47,"minimum_age":48,"maximum_age":24,"healthy_volunteers":49,"eligibility_criteria":50,"std_ages":54,"locations":57,"central_contacts":91,"overall_officials":92,"references":93,"see_also_links":94},"NCT07660640","PBI-AMD-901","Long-Term Follow Up of VOY-101 Non-nAMD Extension Study","Long-Term Follow Up of VOY-101 for Advanced Non-Neovascular Age-Related Macular Degeneration Extension Study","ENROLLING_BY_INVITATION","2031-08-30","2026-02","2026-06-22","2026-03-03","Perceive Biotherapeutics, Inc.","INDUSTRY",true,"Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration","This is a long-term observational, non-interventional extension study to the Phase 1\u002F2a studies that administered VOY-101 to subjects with advanced non-neovascular age-related macular degeneration (AMD).",[19,20],"Age-Related Macular Degeneration (AMD)","Non-Neovascular Age-Related Macular Degeneration",[22],"Long term follow up, extension study","OBSERVATIONAL",null,[],{"count":27,"type":28},88,"ESTIMATED",[30,36],{"type":31,"name":32,"description":33,"armGroupLabels":34},"OTHER","observational study","No intervention - observational study",[35],"Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101",{"type":37,"name":38,"description":39,"armGroupLabels":40},"BIOLOGICAL","VOY-101","One-time intravitreal injection of VOY-101.",[35],[42],{"measure":43,"description":44,"timeFrame":45},"Frequency of ocular and systemic VOY-101 related AEs","Frequency of ocular and systemic VOY-101 related AEs (serious \\[SAEs\\] and treatment-emergent non-serious adverse events \\[TEAEs\\]).","3 years",[],"ALL","50 Years",false,{"inclusion":51,"exclusion":52,"raw_text":53},[],[],"Inclusion Criteria:\n\n1. Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1\u002F2a study of VOY-101.\n2. Are willing and able to understand and provide informed consent.\n\nExclusion Criteria:\n\nThere are no exclusion criteria for this study",[55,56],"ADULT","OLDER_ADULT",[58,67,75,83],{"facility":59,"city":60,"state":61,"zip":62,"country":63,"geoPoint":64},"Ophthalmic Consultants of Boston","Boston","Massachusetts","02114","United States",{"lat":65,"lon":66},42.35843,-71.05977,{"facility":68,"city":69,"state":70,"zip":71,"country":63,"geoPoint":72},"Retina Consultants of Texas","Bellaire","Texas","77401",{"lat":73,"lon":74},29.70579,-95.45883,{"facility":76,"city":77,"state":78,"zip":79,"country":63,"geoPoint":80},"University of Utah","Salt Lake City","Utah","84132",{"lat":81,"lon":82},40.76078,-111.89105,{"facility":84,"city":85,"zip":86,"country":87,"geoPoint":88},"Sourasky Medical Center - Ichilov","Tel Aviv","6423906","Israel",{"lat":89,"lon":90},32.08088,34.78057,[],[],[],[],{"nct_id":4,"conditions":96,"biomarkers":98},[97],"Nonexudative age-related macular degeneration",[],{"nct_id":4,"found":15,"summary":100,"prompt_version":110},{"design":101,"status":102,"heading":103,"summary":104,"follow_up":105,"word_count":106,"commitments":107,"compensation":108,"drugs_mentioned":109},"This is an observational study, meaning no new treatments are given. It is a long-term follow-up for people who previously received VOY-101, with a planned enrollment of 88 participants.","completed","Long-Term Follow Up of VOY-101 for Non-Neovascular Age-Related Macular Degeneration","This study is a long-term follow-up for people who previously received an injection of VOY-101 for advanced non-neovascular age-related macular degeneration (AMD). This is an observational study, meaning you won't receive any new treatments as part of this study. Researchers want to understand the long-term safety of VOY-101 by tracking any side effects related to the eye or body for up to 3 years. To join, you must have previously participated in a VOY-101 study (PBI-AMD-001 or PBI-AMD-002). The current status of this study is unclear, and it plans to enroll 88 participants.","Participants will be followed for 3 years to track the frequency of side effects related to VOY-101.",93,"Not specified in the trial record.","Not stated in the trial record.",[32,38],"v2"]